BiomedicalPublications

Experimental Hematology and Oncology

BioMed Central·United Kingdom·ISSN 2162-3619

Open accessIn DOAJFee waivers availableMedicine

Experimental Hematology and Oncology is published by BioMed Central as an open access journal (ISSN 2162-3619). The list article processing charge is $3,290. Typical time to publication is 6 wks. Its OpenAlex h-index is 76. Primary field: Medicine. It is listed in the Directory of Open Access Journals. Fee waivers are stated as available. Figures on this page are sourced from OpenAlex and DOAJ and should be confirmed on the journal’s own site before submission.

Cost to publish

$3,290

Open-access article processing charge, list price.

Checked · Journal fee page

Time to publication

6 wks

Fast for a peer-reviewed journal — check what review depth that implies.

h-index

76

OpenAlex citation statistic. Not a Journal Impact Factor.

2-year mean citedness

13.1

Average citations to articles from the previous two years.

What it costs to publish here

Publishing an open-access article in Experimental Hematology and Oncology is listed at $3,290. The publisher also lists 2,890 EUR, 2,590 GBP. The journal reports that fee waivers are available — worth pursuing if you are funding this yourself or working from a lower-income country.

The journal's own fee page →

What this journal has charged over time

List price for an open-access article in Experimental Hematology and Oncology, as recorded by OpenAlex for each year. The fee has risen 38% since 2019, from $2,380 to $3,290.

$0$1.6k$3.3k2019: $2,38020192020: $2,49020202021: $2,69020212022: $2,79020222023: $2,99020232024: $3,19020242025: $3,2902025

Publishers change list prices without notice and often apply discounts, institutional agreements or waivers. Treat this as the trend, and confirm the current figure with the journal.

Peer review and licensing

Review modelAnonymous peer review (policy)
LicenceCC BY, CC BY-NC-ND
Author keeps copyrightYes
Plagiarism screeningYes
Editorial boardPublished →
LanguagesEN

Verification checks

8 of 8 confirmed

These are facts we could verify in public records, not a verdict. A journal missing a check is not necessarily disreputable — many long-established subscription journals sit outside the open-access registries entirely. Use them as questions to ask, and confirm anything that matters directly with the journal before you submit.

  • Listed in the Directory of Open Access JournalsDOAJ applies a documented set of inclusion criteria.
  • Included in OpenAlex's curated core setOpenAlex flags well-established venues that appear across major indexes.
  • Peer review model publicly declaredAnonymous peer review
  • Publication charges stated up frontA journal that will not tell you the fee before submission is worth a second look.
  • Screens submissions for plagiarismReported to DOAJ by the journal.
  • Participates in a digital preservation schemeArchiving means the record survives if the publisher does not.
  • Assigns persistent identifiers (DOIs)Standard practice; its absence is unusual.
  • Still actively publishingMost recent indexed article: 2026.

Scope

The subjects Experimental Hematology and Oncology publishes most, derived from the topics assigned to its indexed articles.

CAR-T cell therapy researchAcute Myeloid Leukemia ResearchCancer Immunotherapy and BiomarkersLymphoma Diagnosis and TreatmentImmune Cell Function and InteractionImmunotherapy and Immune ResponsesImmune cells in cancerMultiple Myeloma Research and TreatmentsAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research

Publication record

Indexed articles924
Total citations26,733
i10-index570
Most recent indexed article2026
Open access since2012
All ISSNs2162-3619

Counts reflect what OpenAlex has indexed and will differ from the publisher's own figures. We do not show a founding year: OpenAlex's first-publication dates are distorted by mis-dated records — it puts PLoS ONE in 1806 — and we would rather omit a number than print one we cannot stand behind.